Read more

June 30, 2024
1 min read
Save

Worst Itch Numeric Rating Scale proves valid, reliable for prurigo nodularis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • Patients reported that the instrument’s questions, recall period and response scale were easy to understand.
  • A psychometric analysis showed that the tool also had adequate test-retest reliability.

A new study found that the Worst Itch Numeric Rating Scale is a valid and reliable instrument to capture itch data of patients with prurigo nodularis.

The Worst Itch Numeric Rating Scale (WI-NRS) is a single-item, patient-reported questionnaire designed to measure an individual’s ‘worst itch’ in the past 24 hours on an 11-point rating scale,” Shawn G. Kwatra, MD, professor and chair of dermatology at University of Maryland School of Medicine, and colleagues wrote. “The psychometric properties of WI-NRS for dermatologic conditions, such as psoriasis and [atopic dermatitis], have been well documented; however, evidence supporting its validation in [prurigo nodularis (PN)] is limited.”

Woman in a yellow short scratches her arm.
A new study found that the Worst Itch Numeric Rating Scale is a valid and reliable instrument to capture itch data of patients with prurigo nodularis. Image: Adobe Stock.

In this study, the authors evaluated whether WI-NRS is an efficient tool to measure itch in PN through qualitative interviews with 20 patients. The researchers also included 311 patients in a pooled intention-to-treat, psychometric analysis of two phase 3 trials, PRIME and PRIME2.

Shawn G. Kwatra

Results from the interviews showed that the WI-NRS questions, recall period and response scale were easy to understand and relevant for patients with PN. According to the psychometric analysis, adequate test-retest reliability was reported in 224 stable patients between screening and baseline (intraclass correlation coefficient [ICC] = 0.72; 95% CI, 0.63-0.79) and weeks 8 to 12 (ICC = 0.88; 95% CI, 0.82-0.92).

Moderate to strong correlations were seen between the WI-NRS scores and similar constructs scores such as the Sleep-NRS (absolute correlation coefficient [r] = 0.41). The analysis also showed that the scale was able to distinguish between patients with different severity levels and quality of life effects.

Additionally, changes in the WI-NRS scores were moderately to strongly correlated to changes in Skin Pain-NRS (r = 0.76) and Sleep-NRS (r = 0.40) from baseline to week 12.

The study found a clinically meaningful improvement threshold of 4 points (range, 3-4.5).

“This study confirms the psychometric and content validity of WI-NRS, thereby establishing it to be a clear, comprehensive and relevant tool to measure itch in PN,” the authors concluded.